Rachna T. Shroff, MD, MS, chief, Section of GI Medical Oncology, University of Arizona Cancer Center, discusses actionable targets in intrahepatic and extrahepatic cholangiocarcinoma. 

In intrahepatic cholangiocarcinoma, targetable mutations account for about 30% of all patients, says Shroff. Alterations in 

 make up about 20% of that population while 

 fusions comprise about 10% to 15% of these patients. 

 amplifications or alterations, and homologous recombination deficiencies are also potentially actionable targets. 

Extrahepatic cholangiocarcinoma differs in that 

 fusions are not as frequently expressed, while 

 amplifications are more common. As in intrahepatic disease, 

 is also seen, albeit in a small subset of patients. 

Videos

Rachna T. Shroff, MD, MS, discusses actionable targets in intrahepatic and extrahepatic cholangiocarcinoma. 

Dr. Shroff on Genomic Landscape of Cholangiocarcinoma

Rachna T. Shroff, MD, MS, chief, Section of GI Medical Oncology, University of Arizona Cancer Center, discusses the importance of molecular profiling upon diagnosis in patients with cholangiocarcinoma.

There have been a number of exciting developments over the last few years, Shroff says. This new horizon of molecular profiling is changing the landscape and how patients are approached with this disease. However, the majority of patients diagnosed with cholangiocarcinoma present with advanced disease.

Clinical trials and options beyond standard combination chemotherapy have become very important, Shroff says. Investigators have found that 30% to 40% of patients have targetable mutations that can be identified with molecular profiling. Targeted therapies are under investigation to target some of these molecular abnormalities; therefore, it is necessary for patients to have a standard tissue or liquid biopsy sent for molecular profiling at the time of diagnosis, she adds. This way, physicians can determine an optimal treatment sequence.

View more from the 2019 Gastrointestinal Cancers Symposium 

Rachna T. Shroff, MD, MS, discusses the importance of molecular profiling upon diagnosis in patients with cholangiocarcinoma.

Rachna T. Shroff, MD, MS

Articles

Dr. Shroff on Genomic Landscape of Cholangiocarcinoma

Dr. Shroff Discusses Molecular Profiling in Cholangiocarcinoma